title: [Prevalence of primary mutations in human immunodeficiency virus with resistance to nucleoside analogues in previously untreated patients from Andalusia. Andalusian Group for the Study of Infectious diseases (GAEI)].
abstract: BACKGROUND
  To analyze the frequency of HIV primary mutations to nucleosides analogues in Andalusia.
  
  
  METHODS
  Genotype study (LiPA) of mutations in codons M41L, T69D, K70R, L74V, M184V, T215Y/F and RT75G-S was performed in 106 HIV-naive patients from 12 Andalusian hospitals, with viral load over 5000 copies of RNA/ml.
  
  
  RESULTS
  Reliable results were obtained in 96 patients; 11 of them (11.45%) showed 12 mutations: two in codon 41, four in codon 70, three in codon 184 and three in codon 215. One patient showed two mutations (41 and 215). The presence of mutations only was related to having sex partner and sexual transmission of HIV infection.
  
  
  CONCLUSIONS
  a) The primary mutations to nucleosides in HIV patients from Andalusia was 11.45%; b) mainly involved drugs were AZT and 3Tc, and c) mutations regarding resistance to ddC, ddI o D4T were not found.
authors.affiliation: Sección de Enfermedades Infecciosas. Hospital Universitario Reina Sofía. Córdoba. kindelan@sofia.hrs.sas.cica.es
authors.forename: J M
authors.initials: JM
authors.lastname: Kindelán
authors.forename: R
authors.initials: R
authors.lastname: Giménez-Doménech
authors.forename: E
authors.initials: E
authors.lastname: Vidal-Verdú
authors.forename: J
authors.initials: J
authors.lastname: Madueño
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015704:CD4 Antigens / Q000032:analysis; D003062:Codon / Q000235:genetics; D004279:DNA, Viral / Q000032:analysis; D003627:Data Interpretation, Statistical; D004352:Drug Resistance, Microbial / Q000235:genetics*; D005260:Female; D005838:Genotype; D006678:HIV / Q000187:drug effects* / Q000235:genetics*; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D009154:Mutation; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000032:analysis; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013030:Spain; D019562:Viral Load; D015215:Zidovudine / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D015704:CD4 Antigens; D003062:Codon; D004279:DNA, Viral; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine